1. Home
  2. Investors
  3. News

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedarplus.ca under the Company’s profile.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
November 11, 2015
Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference
November 9, 2015
Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
October 26, 2015
Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum
October 22, 2015
Resverlogix Announces Voting Results
September 30, 2015
Resverlogix Provides Research and Development Update in New York City
September 29, 2015
Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases
September 24, 2015
Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference
September 10, 2015
Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor
August 31, 2015
International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"
August 4, 2015
Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital
July 21, 2015
Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink
July 8, 2015
Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement
June 30, 2015
Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
June 22, 2015
Resverlogix to Present at the 2015 Bio International Convention
June 17, 2015
Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA
June 8, 2015
Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
June 1, 2015
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement
April 27, 2015
Resverlogix Receives Two Patents for RVX-208 in China
April 7, 2015
Resverlogix Presents at the Prestigious American College of Cardiology 64th Annual Scientific Session & Expo (ACC.15)
March 16, 2015
Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program
March 4, 2015
Resverlogix Presents at BIO CEO & Investor Conference
February 10, 2015
Resverlogix Presents at Biotech Showcase During JP Morgan Week
January 15, 2015